Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
Kevin McFarthing, Gary Rafaloff, Marco A. S. Baptista, Leah Mursaleen, Rosie Fuest, Richard K.H. Wyse, Simon Stott
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.3233/jpd-229002 ↗
- Volume · Issue · Pages
- 12 · 4 · 1073-1082
- Publisher
- IOS Press BV
- Article URL
- https://doi.org/10.3233/jpd-229002 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
06 May 2022
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 06 May 2022 | OpenAlex |
Keywords (as given): disease; Parkinson's disease; drug development; clinical trials; symptomatic treatment; disease-modifying therapy; new drugs; drug repurposing; drug reformulation; clinical trial registration; ClinicalTrials.gov
HEC Status at Publication Not the journal's current status
HEC Status at PublicationConclusive
HEC status at publication
Recognized
W
Based on the recorded HEC dataset applicable to the article's publication date. Listed as W in the HEC list for hjrs 2021-22 V2.
- Journal
- Journal of Parkinson's Disease
- Publication date used
- 06 May 2022 (OpenAlex publication date)
- Applicable HEC period
- hjrs 2021-22 V2 (version 1) · 01 Jul 2021 – 30 Jun 2022
- Category
- W
- Recognition status
- Recognized (OK_RECORD_FOUND)
- Source
- hjrs-2021-22 row 3381
- Verification status
- Verified against source · last verified 16 Oct 2026
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.